Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive symbols : Rckt save search
Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Published: 2023-05-19 (Crawled : 12:20) - biospace.com/
RCKT M | $24.075 0.86% 170K
|
Health Technology
|
| O: 2.35%
H: 1.24%
C: 0.6%
positive cell pharmaceuticals meeting cardiovascular therapy
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting
Published: 2022-12-12 (Crawled : 18:00) - biospace.com/
RCKT M | $24.075 0.86% 170K
|
Health Technology
|
| O: 0.84%
H: 7.72%
C: 5.69%
pharmaceuticals meeting positive
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
Published: 2022-09-30 (Crawled : 11:00) - biospace.com/
RCKT M | $24.075 0.86% 170K
|
Health Technology
|
| O: 2.71%
H: 11.12%
C: 10.68%
america pharmaceuticals disease meeting heart trial positive rp-a501 danon disease phase 1
Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Published: 2022-05-19 (Crawled : 12:00) - biospace.com/
RCKT M | $24.075 0.86% 170K
|
Health Technology
|
| O: -1.95%
H: 5.37%
C: -0.5%
program positive therapy topline
Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Published: 2022-05-16 (Crawled : 12:00) - biospace.com/
RCKT M | $24.075 0.86% 170K
|
Health Technology
|
| O: 9.74%
H: 4.82%
C: -0.77%
anemia positive therapy danon disease
Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 15:00) - biospace.com/
RCKT M | $24.075 0.86% 170K
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
treatment ema als anemia gene therapies positive gene therapy
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease
Published: 2021-11-15 (Crawled : 13:00) - biospace.com/
RCKT M | $24.075 0.86% 170K
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: -23.94%
disease phase 1 positive trial phase 2 phase 3 rp-a501 danon disease
Rocket Pharmaceuticals Announces Positive Clinical Data from RP-L201 Trial for the Treatment of LAD-I at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
Published: 2021-10-20 (Crawled : 10:00) - biospace.com/
RCKT M | $24.075 0.86% 170K
|
Health Technology
|
| O: 6.15%
H: 1.44%
C: -2.95%
treatment europe positive therapy trial
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24th Annual Meeting of the American Society of Gene and Cell Therapy
Published: 2021-05-13 (Crawled : 12:00) - biospace.com/
RCKT M | $24.075 0.86% 170K
|
Health Technology
|
| O: 1.61%
H: 3.67%
C: -3.17%
positive therapy anemia
Rocket Pharmaceuticals Reports Positive Long-Term Clinical Data from RP-L201 Trial for the Treatment of Leukocyte Adhesion Deficiency-I at the Clinical Immunology Society 2021 Annual Meeting
Published: 2021-04-14 (Crawled : 12:00) - biospace.com/
RCKT M | $24.075 0.86% 170K
|
Health Technology
|
| O: 0.88%
H: 7.34%
C: 2.57%
treatment positive immunology trial
Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency
Published: 2021-03-22 (Crawled : 12:00) - biospace.com/
RCKT M | $24.075 0.86% 170K
|
Health Technology
|
| O: -0.64%
H: 7.12%
C: 1.8%
treatment phase 1 positive trial phase 3 phase 2
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.74 119.2% 52M
|
Finance
CZOO | $9.07 81.76% 22M
|
EDBL | News | $6.56 74.47% 1.8M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.7945 32.42% 3.1M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
BTCM | $3.45 27.78% 640K
|
Arts, Entertainment, and Recrea...
PALI | $6.29 27.59% 22M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.